This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Best Momentum Stock to Buy for August 19th
by Zacks Equity Research
UCBJF, STX and AXS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 19, 2024.
Here's Why Momentum in UCB SA (UCBJF) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, UCB SA (UCBJF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"
by Zacks Equity Research
UCB SA (UCBJF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate
by Zacks Equity Research
Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.
Pharma Stocks Weighed Down by Competition, Generic Pressure
by Zacks Equity Research
Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.
Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session
by Zacks Equity Research
Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
by Zacks Equity Research
Parkinson's disease is a lucrative area due to lack of curative therapy in this space. Many players are trying to bring new treatments to the market. A lot has happened in last couple of months.
Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA
by Zacks Equity Research
Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).
Key FDA Events to Watch Out for in Jul 2017
by Arpita Dutt
Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?
Adamas Provides Positive Long-term Data on Parkinson's Drug
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
by Zacks Equity Research
Glaxo carries a Zacks Rank #2 (Buy).
Amgen Files for Approval of Osteoporosis Drug in Japan
by Zacks Equity Research
Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
Pharma Stock Outlook: Let's Make a Deal
by Arpita Dutt
M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.
Pharma Stock Outlook: Let's Make a Deal
by Arpita Dutt
M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.